{"pmid":32492530,"title":"Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity.","text":["Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity.","OBJECTIVES: We hypothesized that immune response may contribute to progression of coronavirus disease-19 (COVID-19) at the second week of illness. Therefore, we compared cell-mediated immune (CMI) responses between severe and mild COVID-19 cases. METHODS: We examined peripheral blood mononuclear cells of laboratory-confirmed COVID-19 patients from their first and third weeks of illness. Severe pneumonia was defined as an oxygen saturation </= 93% at room air. Expressions of molecules related to T-cell activation and functions were analyzed by flow cytometry. RESULTS: The population dynamics of T cells at the first week were not different between the two groups. However, total numbers of CD4+ and CD8 + T cells tended to be lower in the severe group at the third week of illness. Expressions of Ki-67, PD-1, perforin, and granzyme B in CD4(+) or CD8(+) T cells were significantly higher in the severe group than in the mild group at the third week. In contrast to the mild group, the levels of their expression did not decrease in severe group. CONCLUSIONS: Severe COVID-19 had higher degree of proliferation, activation, and cytotoxicity of T-cells at the late phase of illness without cytotoxic T-cell contraction, which might contribute to the development of severe COVID-19.","Int J Infect Dis","Kang, Chang Kyung","Han, Gi-Chan","Kim, Minji","Kim, Gwanghun","Shin, Hyun Mu","Song, Kyoung-Ho","Choe, Pyoeng Gyun","Park, Wan Beom","Kim, Eu Suk","Kim, Hong Bin","Kim, Nam-Joong","Kim, Hang-Rae","Oh, Myoung-Don","32492530"],"abstract":["OBJECTIVES: We hypothesized that immune response may contribute to progression of coronavirus disease-19 (COVID-19) at the second week of illness. Therefore, we compared cell-mediated immune (CMI) responses between severe and mild COVID-19 cases. METHODS: We examined peripheral blood mononuclear cells of laboratory-confirmed COVID-19 patients from their first and third weeks of illness. Severe pneumonia was defined as an oxygen saturation </= 93% at room air. Expressions of molecules related to T-cell activation and functions were analyzed by flow cytometry. RESULTS: The population dynamics of T cells at the first week were not different between the two groups. However, total numbers of CD4+ and CD8 + T cells tended to be lower in the severe group at the third week of illness. Expressions of Ki-67, PD-1, perforin, and granzyme B in CD4(+) or CD8(+) T cells were significantly higher in the severe group than in the mild group at the third week. In contrast to the mild group, the levels of their expression did not decrease in severe group. CONCLUSIONS: Severe COVID-19 had higher degree of proliferation, activation, and cytotoxicity of T-cells at the late phase of illness without cytotoxic T-cell contraction, which might contribute to the development of severe COVID-19."],"journal":"Int J Infect Dis","authors":["Kang, Chang Kyung","Han, Gi-Chan","Kim, Minji","Kim, Gwanghun","Shin, Hyun Mu","Song, Kyoung-Ho","Choe, Pyoeng Gyun","Park, Wan Beom","Kim, Eu Suk","Kim, Hong Bin","Kim, Nam-Joong","Kim, Hang-Rae","Oh, Myoung-Don"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492530","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ijid.2020.05.106","keywords":["covid-19","contraction","cytotoxic t cell","granzyme b","perforin","severity"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668623433541353472,"score":9.490897,"similar":[{"pmid":32442287,"title":"Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.","text":["Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.","BACKGROUND: We previously reported that lymphocytopenia and T cell exhaustion is notable in acute COVID19 patients, especially in aged and severe cases. Thymosin alpha 1 (Talpha1) had been used in the treatment of viral infections as an immune response modifier for many years. However, clinical benefits and mechanism of Talpha1 supplement to COVID-19 are still unclear. METHODS: We retrospectively reviewed the clinical outcomes of 76 severe cases with COVID-19 admitted into two hospitals in Wuhan from December 2019 to March 2020. The thymus output in peripheral blood mononuclear cells (PBMCs) from COVID-19 patients was measured by T cell receptor excision circles (TREC). The levels of T cell exhaustion markers PD-1 and Tim-3 on CD8+ T cells were detected by flow cytometry. RESULTS: Compared with untreated group, Talpha1 treatment significantly reduces mortality of severe COVID-19 patients (11.11% vs. 30.00%, p=0.044). Talpha1 timely enhances blood T cell numbers in COVID-19 patients with severe lymphocytopenia (the counts of CD8+ T cells or CD4+ T cells in circulation lower than 400/muL or 650/muL, respectively). Under such conditions, Talpha1 also successfully restores CD8+ and CD4+ T cell numbers in aged patients. Meanwhile, Talpha1 reduces PD-1 and Tim-3 expression on CD8+ T cells from severe COVID-19 patients in comparison with untreated cases. It is of note that restoration of lymphocytopenia and acute exhaustion of T cells are roughly parallel to the rise of TRECs. CONCLUSIONS: Talpha1 supplement significantly reduce mortality of severe COVID-19 patients. COVID-19 patients with the counts of CD8+ T cells or CD4+ T cells in circulation lower than 400/muL or 650/muL, respectively, gain more benefits from Talpha1. Talpha1 reverses T cell exhaustion and recovers immune reconstitution through promoting thymus output during SARS-CoV-2 infection.","Clin Infect Dis","Liu, Yueping","Pang, Yue","Hu, Zhenhong","Wu, Ming","Wang, Chenhui","Feng, Zeqing","Mao, Congzheng","Tan, Yingjun","Liu, Ying","Chen, Li","Li, Min","Wang, Gang","Yuan, Zilin","Diao, Bo","Wu, Yuzhang","Chen, Yongwen","32442287"],"abstract":["BACKGROUND: We previously reported that lymphocytopenia and T cell exhaustion is notable in acute COVID19 patients, especially in aged and severe cases. Thymosin alpha 1 (Talpha1) had been used in the treatment of viral infections as an immune response modifier for many years. However, clinical benefits and mechanism of Talpha1 supplement to COVID-19 are still unclear. METHODS: We retrospectively reviewed the clinical outcomes of 76 severe cases with COVID-19 admitted into two hospitals in Wuhan from December 2019 to March 2020. The thymus output in peripheral blood mononuclear cells (PBMCs) from COVID-19 patients was measured by T cell receptor excision circles (TREC). The levels of T cell exhaustion markers PD-1 and Tim-3 on CD8+ T cells were detected by flow cytometry. RESULTS: Compared with untreated group, Talpha1 treatment significantly reduces mortality of severe COVID-19 patients (11.11% vs. 30.00%, p=0.044). Talpha1 timely enhances blood T cell numbers in COVID-19 patients with severe lymphocytopenia (the counts of CD8+ T cells or CD4+ T cells in circulation lower than 400/muL or 650/muL, respectively). Under such conditions, Talpha1 also successfully restores CD8+ and CD4+ T cell numbers in aged patients. Meanwhile, Talpha1 reduces PD-1 and Tim-3 expression on CD8+ T cells from severe COVID-19 patients in comparison with untreated cases. It is of note that restoration of lymphocytopenia and acute exhaustion of T cells are roughly parallel to the rise of TRECs. CONCLUSIONS: Talpha1 supplement significantly reduce mortality of severe COVID-19 patients. COVID-19 patients with the counts of CD8+ T cells or CD4+ T cells in circulation lower than 400/muL or 650/muL, respectively, gain more benefits from Talpha1. Talpha1 reverses T cell exhaustion and recovers immune reconstitution through promoting thymus output during SARS-CoV-2 infection."],"journal":"Clin Infect Dis","authors":["Liu, Yueping","Pang, Yue","Hu, Zhenhong","Wu, Ming","Wang, Chenhui","Feng, Zeqing","Mao, Congzheng","Tan, Yingjun","Liu, Ying","Chen, Li","Li, Min","Wang, Gang","Yuan, Zilin","Diao, Bo","Wu, Yuzhang","Chen, Yongwen"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442287","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1093/cid/ciaa630","keywords":["covid-19","immune reconstitution","sars-cov-2","t cell exhaustion","thymosin alpha 1"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667523504761733120,"score":372.9878},{"pmid":32325421,"pmcid":"PMC7194879","title":"Increased expression of CD8 marker on T-cells in COVID-19 patients.","text":["Increased expression of CD8 marker on T-cells in COVID-19 patients.","BACKGROUND: Cell-mediated immunity including T-cells (T helper and cytotoxic) plays an essential role in efficient antiviral responses against coronavirus disease-2019 (COVID-19). Therefore, in this study, we evaluated the ratio and expression of CD4 and CD8 markers in COVID-19 patients to clarify the immune characterizations of CD4 and CD8 T-cells in COVID-19 patients. METHODS: Peripheral blood samples of 25 COVID-19 patients and 25 normal individuals with similar age and sex as the control group were collected. White blood cells, platelets, and lymphocytes were counted and CD4 and CD8 T lymphocytes were evaluated by flow cytometry. RESULTS: The number of white blood cells, lymphocytes, and platelets were reduced significantly in COVID-19 patients (P < 0.05). The difference in CD4:CD8 ratio, CD4 T-cell frequency, CD8 T-cell frequency, and CD4 mean fluorescence intensity (MFI) was not significant between COVID-19 patients and healthy individuals (P > 0.05); however, the CD8 MFI increased significantly in COVID-19 infected patients (P < 0.05). CONCLUSION: Although, there is no significant difference in the ratio of CD4 to CD8 between two groups, the expression level of CD8 in COVID-19 patients was significantly higher than the normal individuals. This result suggested that the cellular immune responses triggered by COVID-19 infection were developed through overexpression of CD8 and hyperactivation of cytotoxic T lymphocytes.","Blood Cells Mol Dis","Ganji, Ali","Farahani, Iman","Khansarinejad, Behzad","Ghazavi, Ali","Mosayebi, Ghasem","32325421"],"abstract":["BACKGROUND: Cell-mediated immunity including T-cells (T helper and cytotoxic) plays an essential role in efficient antiviral responses against coronavirus disease-2019 (COVID-19). Therefore, in this study, we evaluated the ratio and expression of CD4 and CD8 markers in COVID-19 patients to clarify the immune characterizations of CD4 and CD8 T-cells in COVID-19 patients. METHODS: Peripheral blood samples of 25 COVID-19 patients and 25 normal individuals with similar age and sex as the control group were collected. White blood cells, platelets, and lymphocytes were counted and CD4 and CD8 T lymphocytes were evaluated by flow cytometry. RESULTS: The number of white blood cells, lymphocytes, and platelets were reduced significantly in COVID-19 patients (P < 0.05). The difference in CD4:CD8 ratio, CD4 T-cell frequency, CD8 T-cell frequency, and CD4 mean fluorescence intensity (MFI) was not significant between COVID-19 patients and healthy individuals (P > 0.05); however, the CD8 MFI increased significantly in COVID-19 infected patients (P < 0.05). CONCLUSION: Although, there is no significant difference in the ratio of CD4 to CD8 between two groups, the expression level of CD8 in COVID-19 patients was significantly higher than the normal individuals. This result suggested that the cellular immune responses triggered by COVID-19 infection were developed through overexpression of CD8 and hyperactivation of cytotoxic T lymphocytes."],"journal":"Blood Cells Mol Dis","authors":["Ganji, Ali","Farahani, Iman","Khansarinejad, Behzad","Ghazavi, Ali","Mosayebi, Ghasem"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32325421","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.bcmd.2020.102437","keywords":["2019-ncov","cd4 lymphocyte","cd8 lymphocyte","covid-19","coronavirus"],"topics":["Mechanism"],"weight":1,"_version_":1666138493884039168,"score":356.34247},{"pmid":32405080,"pmcid":"PMC7219428","title":"Decreased T cell populations contribute to the increased severity of COVID-19.","text":["Decreased T cell populations contribute to the increased severity of COVID-19.","Background: We observe changes of the main lymphocyte subsets (CD16(+)CD56CD19CD3CD4and CD8) in COVID-19-infected patients and explore whether the changes are associated with disease severity. Methods: One-hundred fifty-four cases of COVID-19-infected patients were selected and divided into 3 groups (moderate group, severe group and critical group). The flow cytometry assay was performed to examine the numbers of lymphocyte subsets. Results: CD3(+), CD4(+) and CD8+ T lymphocyte subsets were decreased in COVID-19-infected patients. Compared with the moderate group and the sever group, CD3(+), CD4(+) and CD8(+) T cells in the critical group decreased greatly (P < 0.001, P= 0.005 or P = 0.001). Conclusions: Reduced CD3(+), CD4(+), CD8(+) T lymphocyte counts may reflect the severity of the COVID-19. Monitoring T cell changes has important implications for the diagnosis and treatment of severe patients who may become critically ill.","Clin Chim Acta","Liu, Rui","Wang, Ying","Li, Jie","Han, Huan","Xia, Zunen","Liu, Fang","Wu, Kailang","Yang, Lan","Liu, Xinghui","Zhu, Chengliang","32405080"],"abstract":["Background: We observe changes of the main lymphocyte subsets (CD16(+)CD56CD19CD3CD4and CD8) in COVID-19-infected patients and explore whether the changes are associated with disease severity. Methods: One-hundred fifty-four cases of COVID-19-infected patients were selected and divided into 3 groups (moderate group, severe group and critical group). The flow cytometry assay was performed to examine the numbers of lymphocyte subsets. Results: CD3(+), CD4(+) and CD8+ T lymphocyte subsets were decreased in COVID-19-infected patients. Compared with the moderate group and the sever group, CD3(+), CD4(+) and CD8(+) T cells in the critical group decreased greatly (P < 0.001, P= 0.005 or P = 0.001). Conclusions: Reduced CD3(+), CD4(+), CD8(+) T lymphocyte counts may reflect the severity of the COVID-19. Monitoring T cell changes has important implications for the diagnosis and treatment of severe patients who may become critically ill."],"journal":"Clin Chim Acta","authors":["Liu, Rui","Wang, Ying","Li, Jie","Han, Huan","Xia, Zunen","Liu, Fang","Wu, Kailang","Yang, Lan","Liu, Xinghui","Zhu, Chengliang"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405080","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.cca.2020.05.019","keywords":["cd3+ t cells","cd4+ t cells","cd8+ t cells","covid-19","lymphocyte subsets"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666802845513416704,"score":322.004},{"pmid":32324595,"title":"The laboratory tests and host immunity of COVID-19 patients with different severity of illness.","text":["The laboratory tests and host immunity of COVID-19 patients with different severity of illness.","BACKGROUND: The Coronavirus Disease-2019 (COVID-19), infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a severe outbreak in China. The host immunity of COVID-19 patients is unknown. METHODS: The routine laboratory tests and host immunity in COVID-19 patients with different severity of illness were compared after patient admission. RESULTS: A total of 65 SARS-CoV-2-positive patients were classified as mild (n=30), severe (n=20), and extremely severe (n=15) illness. Many routine laboratory tests such as ferritin, lactate dehydrogenase and D-dimer were increased in severe and extremely severe patients. The absolute numbers of CD4+ T cells, CD8+ T cells and B cells were all gradually decreased with increased severity of illness. The activation markers such as HLA-DR and CD45RO expressed on CD4+ and CD8+ T cells were increased in severe and extremely severe patients compared with mild patients. The co-stimulatory molecule CD28 had opposite results. The percentage of natural regulatory T cells was decreased in extremely severe patients. The percentage of IFN-gamma producing CD8+ T cells was increased in both severe and extremely severe patients compared with mild patients. The percentage of IFN-gamma producing CD4+ T cells was increased in extremely severe patients. The IL-2R, IL-6, and IL-10 were all increased in extremely severe patients. The activation of DC and B cells was decreased in extremely severe patients. CONCLUSIONS: The number and function of T cells are inconsistent in COVID-19 patients. The hyperfunction of CD4+ and CD8+ T cells is associated with the pathogenesis of extremely severe SARS-CoV-2 infection.","JCI Insight","Wang, Feng","Hou, Hongyan","Luo, Ying","Tang, Guoxing","Wu, Shiji","Huang, Min","Liu, Weiyong","Zhu, Yaowu","Lin, Qun","Mao, Liyan","Fang, Minghao","Zhang, Huilan","Sun, Ziyong","32324595"],"abstract":["BACKGROUND: The Coronavirus Disease-2019 (COVID-19), infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a severe outbreak in China. The host immunity of COVID-19 patients is unknown. METHODS: The routine laboratory tests and host immunity in COVID-19 patients with different severity of illness were compared after patient admission. RESULTS: A total of 65 SARS-CoV-2-positive patients were classified as mild (n=30), severe (n=20), and extremely severe (n=15) illness. Many routine laboratory tests such as ferritin, lactate dehydrogenase and D-dimer were increased in severe and extremely severe patients. The absolute numbers of CD4+ T cells, CD8+ T cells and B cells were all gradually decreased with increased severity of illness. The activation markers such as HLA-DR and CD45RO expressed on CD4+ and CD8+ T cells were increased in severe and extremely severe patients compared with mild patients. The co-stimulatory molecule CD28 had opposite results. The percentage of natural regulatory T cells was decreased in extremely severe patients. The percentage of IFN-gamma producing CD8+ T cells was increased in both severe and extremely severe patients compared with mild patients. The percentage of IFN-gamma producing CD4+ T cells was increased in extremely severe patients. The IL-2R, IL-6, and IL-10 were all increased in extremely severe patients. The activation of DC and B cells was decreased in extremely severe patients. CONCLUSIONS: The number and function of T cells are inconsistent in COVID-19 patients. The hyperfunction of CD4+ and CD8+ T cells is associated with the pathogenesis of extremely severe SARS-CoV-2 infection."],"journal":"JCI Insight","authors":["Wang, Feng","Hou, Hongyan","Luo, Ying","Tang, Guoxing","Wu, Shiji","Huang, Min","Liu, Weiyong","Zhu, Yaowu","Lin, Qun","Mao, Liyan","Fang, Minghao","Zhang, Huilan","Sun, Ziyong"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324595","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1172/jci.insight.137799","keywords":["adaptive immunity","cellular immune response","immunology","infectious disease","innate immunity"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138493807493120,"score":308.6522},{"pmid":32463803,"title":"Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.","text":["Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.","BACKGROUND: Coronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Anti-viral immune response is crucial to achieve pathogen clearance, however in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options. METHODS: We performed a flow cytometric characterization of immune cells subsets from 30 COVID-19 patients and correlated these data with clinical outcomes. RESULTS: COVID-19 patients showed decreased numbers of circulating T, B and NK cells, and exhibited a skewing of CD8+ T cells towards a terminally differentiated/senescent phenotype. In agreement, T CD4+, T CD8+ but also NK cells displayed reduced anti-viral cytokine production capability. Moreover, a reduced cytotoxic potential was identified in COVID-19 patients, particularly in those that required intensive care. The latter group of patients showed also increased serum IL-6 levels, that correlated to the frequency of granzyme-expressing NK cells. Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells. CONCLUSION: In conclusion, the association between IL-6 serum levels and the impairment of cytotoxic activity suggests the possibility that targeting this cytokine may restore anti-viral mechanisms. FUNDING: This study was supported by funds of Dept. of Experimental and Clinical Medicine of University of Florence (ex-60%) derived from Ministero dell'Istruzione, dell'Universita e della Ricerca (Italy).","J Clin Invest","Mazzoni, Alessio","Salvati, Lorenzo","Maggi, Laura","Capone, Manuela","Vanni, Anna","Spinicci, Michele","Mencarini, Jessica","Caporale, Roberto","Peruzzi, Benedetta","Antonelli, Alberto","Trotta, Michele","Zammarchi, Lorenzo","Ciani, Luca","Gori, Leonardo","Lazzeri, Chiara","Matucci, Andrea","Vultaggio, Alessandra","Rossi, Oliviero","Almerigogna, Fabio","Parronchi, Paola","Fontanari, Paolo","Lavorini, Federico","Peris, Adriano","Rossolini, Gian Maria","Bartoloni, Alessandro","Romagnani, Sergio","Liotta, Francesco","Annunziato, Francesco","Cosmi, Lorenzo","32463803"],"abstract":["BACKGROUND: Coronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Anti-viral immune response is crucial to achieve pathogen clearance, however in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options. METHODS: We performed a flow cytometric characterization of immune cells subsets from 30 COVID-19 patients and correlated these data with clinical outcomes. RESULTS: COVID-19 patients showed decreased numbers of circulating T, B and NK cells, and exhibited a skewing of CD8+ T cells towards a terminally differentiated/senescent phenotype. In agreement, T CD4+, T CD8+ but also NK cells displayed reduced anti-viral cytokine production capability. Moreover, a reduced cytotoxic potential was identified in COVID-19 patients, particularly in those that required intensive care. The latter group of patients showed also increased serum IL-6 levels, that correlated to the frequency of granzyme-expressing NK cells. Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells. CONCLUSION: In conclusion, the association between IL-6 serum levels and the impairment of cytotoxic activity suggests the possibility that targeting this cytokine may restore anti-viral mechanisms. FUNDING: This study was supported by funds of Dept. of Experimental and Clinical Medicine of University of Florence (ex-60%) derived from Ministero dell'Istruzione, dell'Universita e della Ricerca (Italy)."],"journal":"J Clin Invest","authors":["Mazzoni, Alessio","Salvati, Lorenzo","Maggi, Laura","Capone, Manuela","Vanni, Anna","Spinicci, Michele","Mencarini, Jessica","Caporale, Roberto","Peruzzi, Benedetta","Antonelli, Alberto","Trotta, Michele","Zammarchi, Lorenzo","Ciani, Luca","Gori, Leonardo","Lazzeri, Chiara","Matucci, Andrea","Vultaggio, Alessandra","Rossi, Oliviero","Almerigogna, Fabio","Parronchi, Paola","Fontanari, Paolo","Lavorini, Federico","Peris, Adriano","Rossolini, Gian Maria","Bartoloni, Alessandro","Romagnani, Sergio","Liotta, Francesco","Annunziato, Francesco","Cosmi, Lorenzo"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463803","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1172/JCI138554","keywords":["cellular immune response","cytokines","immunology","infectious disease","nk cells"],"locations":["Dept. of"],"countries":["Turkey"],"countries_codes":["TUR|Turkey"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521480310785,"score":305.9678}]}